Published in final edited form as:

J Neurochem. 2010 March ; 112(5): 1286–1294. doi:10.1111/j.1471-4159.2009.06545.x.

Cholesterol modulates ion channels via down-regulation of phosphatidylinositol 4,5-bisphosphate

Yoon Sun Chun^{*}, Sora Shin^{*}, Yonjung Kim^{*}, Hana Cho^{*}, Myoung Kyu Park^{*}, Tae-Wan Kim[†], Sergey V. Voronov[‡], Gilbert Di Paolo[†], Byung-Chang Suh[‡], and Sungkwon Chung^{*}

^{*}Department of Physiology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, South Korea

[†]Department of Pathology, Columbia University Medical Center, New York, NY, USA

[‡]Department of Physiology and Biophysics, University of Washington School of Medicine, Seattle, WA, USA

Abstract

Ubiquitously expressed Mg²⁺-inhibitory cation (MIC) channels are permeable to Ca²⁺ and Mg²⁺ and are essential for cell viability. When membrane cholesterol level was increased by pre-incubating cells with a water-soluble form of cholesterol, the endogenous MIC current in HEK293 cells was negatively regulated. The application of phosphatidylinositol 4,5-bisphosphate (PIP₂) recovered MIC current from cholesterol effect. As PIP₂ is the direct modulator for MIC channels, high cholesterol content may cause down-regulation of PIP₂. To test this possibility, we examined the effect of cholesterol on two exogenously expressed PIP₂-sensitive K⁺ channels: human *Ether-a-go-go* related gene (HERG) and KCNQ. Enrichment with cholesterol inhibited HERG currents, while inclusion of PIP₂ in the pipette solution blocked the cholesterol effect. KCNQ channel was also inhibited by cholesterol. The effects of cholesterol on these channels were blocked by pre-incubating cells with inhibitors for phospholipase C, which may indicate that cholesterol enrichment induces the depletion of PIP₂ via phospholipase C activation. Lipid analysis showed that cholesterol enrichment reduced γ -³²P incorporation into PIP₂ by approximately 35%. Our results suggest that cholesterol may modulate ion channels by changing the levels of PIP₂. Thus, an important cross-talk exists among two plasma membrane-enriched lipids, cholesterol and PIP₂.

Keywords

cholesterol; human *Ether-a-go-go* related gene; Mg²⁺-inhibitory cation channel; phosphatidylinositol 4,5-bisphosphate; phospholipase C

Cholesterol constitutes a key component of the mammalian plasma membrane and is capable of influencing its structural and physical properties such as fluidity, curvature and stiffness. Therefore, cholesterol levels may affect the function of various ion channels and receptors in the plasma membrane. Cholesterol is known to be essential for the functionality of the nicotinic acetylcholine receptor because it is necessary for maintaining proper lipid–protein interaction (Fong and McNamee 1986). Manipulation of cholesterol content affects the equilibrium between the closed and open states of volume-regulated anion channels (Levitan *et al.* 2000). Similarly, cholesterol content affects the kinetic and steady-state parameters of activation and

inactivation of voltage-dependent K⁺ (Kv1.3) channels in activated T lymphocytes (Hajdu *et al.* 2003), as well as structural coupling between L-type Ca²⁺ channels and adjacent regulatory proteins in ventricular myocytes (Tsujikawa *et al.* 2008). Cholesterol content has been shown to affect the gating of Ca²⁺-activated K⁺ channels in vascular smooth muscle cells (Chang *et al.* 1995). In some cases, cholesterol content regulates the formation of lipid raft micro-domain structures, thereby regulating the targeting of K⁺ channels (Romanenko *et al.* 2004; Abi-Char *et al.* 2007), the activity of large-conductance Ca²⁺-activated K⁺ channels from colonic epithelia (Lam *et al.* 2004), and the surface expression of TRPC3 channels (Graziani *et al.* 2006). Collectively, these studies imply that cholesterol content may directly affect lipid-channel protein interactions, change channel gating kinetics and participate in targeting channels to specific micro-domains.

The various effects of cholesterol on ion channels are thought to occur through direct physical interactions with other lipids or target proteins. Alternatively, cholesterol may modulate ion channel activities by changing the signaling properties of the plasma membrane. For example, phosphoinositides (i.e. phosphorylated derivatives of phosphatidylinositol) are major signaling molecules found in the cell membrane. Among them, phosphatidylinositol 4,5-bisphosphate (PIP₂) plays a fundamental role in the plasma membrane, where it regulates signal transduction, exocytosis/endocytosis, actin dynamics, and ion channel and transporter function (Suh and Hille 2005; Di Paolo and De Camilli 2006). For instance, a large number of ion channels have been shown to be inhibited when PIP₂ is hydrolyzed by phospholipase C (PLC) (Suh and Hille 2005). In this study, we showed that increased cholesterol content decreases PIP₂ levels and inhibits PIP₂-sensitive channels, including the endogenous Mg²⁺-inhibitory cation (MIC) channel and the exogenously expressed HERG K⁺ and KCNQ K⁺ channels. Cholesterol also acutely inhibited the HERG current. The inclusion of PIP₂ or PLC inhibitors in the pipette solution prevented acute inhibition by cholesterol. Also, pre-incubating cells with PLC inhibitors prevented cholesterol effect on these channels, indicating that increasing cholesterol levels activate the PLC pathway. Taken together, our results suggest that one of novel function of cholesterol is to modulate ion channels via regulation of PIP₂ level.

Materials and methods

All chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA), except for U73122 (Research Biochemicals, Natick, MA, USA), *m*-3M3 fetal bovine serum (FBS), *o*-3M3FBS (Tocris, Ellisville, MO, USA) and edelfosine (Calbiochem, Gibbstown, NJ, USA). Phosphatidylinositol phosphates including DiC₈-PIP₂ and phosphatidic acid (PA) were dissolved in pipette solutions for whole-cell recordings and sonicated for 10 min at ice-cold temperature just before use.

Cell culture

Human embryonic kidney (HEK)293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% heat-inactivated FBS and penicillin/streptomycin at 37°C in a 5% CO₂ incubator. To enrich the cells with cholesterol, we exposed them to DMEM culture medium containing cholesterol water-solubilized with methyl- β -cyclodextrin (M β CD-cholesterol) for 1–2 h. During the incubation, cells were maintained in a humidified CO₂ incubator at 37°C. HERG cDNA was cloned into *Bam*HI/*Eco*RI sites of the plasmid pCDNA3.0 (Invitrogen, Carlsbad, CA, USA). DNA sequencing was used to verify the integrity of the HERG. HEK293 cells were transiently co-transfected with HERG-pCDNA3.0 and a green fluorescent protein cDNA plasmid (Clontech Laboratories, Mountain View, CA, USA) using the lipofectamine method (Invitrogen). Cells with green fluorescence were used for a patch clamp 24–48 h after transfection. For electrophysiologic analysis, cells were harvested with trypsinization, washed with phosphate-buffered saline (PBS), and studied within 8 h of harvest.

Human embryonic kidney tsA-201 (tsA) cells were cultured and transiently transfected using lipofectamine with various cDNAs: M1-muscarinic receptor and the channel subunits KCNQ2 and KCNQ3. TsA cells were maintained in DMEM supplemented with 10% FBS and 0.2% penicillin/streptomycin and used 24–48 h after transfection on poly-L-lysine-coated coverslips.

Cholesterol assay

Cells grown in 100 mm plates were assayed in duplicate for cholesterol using the Amplex red cholesterol assay kit (Molecular Probes, Eugene, OR, USA). First, cells were incubated for 2 h with MβCD-cholesterol, washed twice with ice-cold PBS and homogenized with hypotonic buffer (10 mM Tris-HCl, pH 7.5, 5 mM MgCl₂, 2 mM EGTA, 25 mM beta-glycerol phosphate, 5 mM sodium fluoride, 2 mM sodium pyrophosphate and 1 mM sodium orthovanadate) using a 22-gauge needle. The samples were then centrifuged at 1000 g for 10 min to remove nuclei and cell debris. Membranes were pelleted from the post-nuclear supernatants by centrifugation for 1 h at 100 000 g, then assayed according to the supplier's instructions.

Cell viability assay

Cell viability was assessed by using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay. Briefly, around 2×10^4 cells per well were seeded in 96-well microtiter plates with 100 μL of medium. After incubating cells in different conditions, 10 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (5 mg/mL stock in PBS) was added to each well and subsequently incubated for 1 h at 37°C. Absorption readings were performed at 540 nm with reference at 690 nm.

Electrophysiology

Patch pipettes were fabricated from borosilicate glass (TW150-4; World Precision Instrument, Sarasota, FL, USA) using a Flaming/Brown micropipette puller (P-97; Sutter Instrument, Novato, CA, USA). Patch-clamp experiments were conducted in a standard whole-cell recording configuration at 23–25°C. For MIC current, extracellular Na⁺-based divalent cation-free recording solution contained: 130 mM sodium methanesulfonate, 5 mM NaCl, 10 mM HEPES and 12 mM N-hydroxyethyl-ethylenediamine-triacetic acid. pH was adjusted to 7.2 with NaOH. In the absence of divalent cations, MIC channels conduct large Na⁺ inward current (Aarts *et al.* 2003). To prevent activation of Ca²⁺ release-activated Ca²⁺ (CRAC), the internal-free [Ca²⁺] was buffered at 100 nM, calculated using Maxchelator software (Stanford University). The fully developed MIC current was almost completely blocked by 2-aminoethoxydiphenyl borate (Jeong *et al.* 2006), and the conductance decreased significantly by the presence of Ca²⁺ in extracellular solution as shown previously (Aarts *et al.* 2003). For the recording of CRAC current separately from MIC current, extracellular Ca²⁺-containing bath solution was used, which contained: 135 mM sodium methanesulfonate, 3 mM CaCl₂, 0.5 mM EDTA and 10 mM HEPES. pH was adjusted to 7.2 with NaOH. Pipette solution contained: 135 mM Cs methanesulfonate, 10 mM 1,2-bis(2-aminophenoxy)ethane-N,N',N'-tetraacetic acid, 10 mM HEPES and 5 mM MgCl₂. Intracellular Mg²⁺ prevents the activation of MIC current (Hermosura *et al.* 2002). pH was adjusted to 7.2 with CsOH. Thapsigargin (1 μM) and inositol trisphosphate (IP₃; 1 μM) were also included in pipette solution to deplete the intracellular Ca²⁺ store. For Kv current recordings, the bath solution contained: 140 mM NaCl, 3 mM MgCl₂, 10 mM HEPES, 5 mM KCl, 10 mM glucose (pH adjusted to 7.4 with NaOH). Pipette solution contained: 140 mM KCl, 5 mM NaCl, 1 mM MgCl₂, 10 mM HEPES, 5 mM EGTA, 2 mM Na-ATP and 1 mM Na-GTP (pH adjusted to 7.4 with KOH). Junction potentials were zeroed with the electrode in the standard bath solution.

Currents were amplified using an Axopatch 1D patch-clamp amplifier (Axon Instruments, Foster City, CA, USA). For KCNQ current and HERG current, transfected TsA cells and HEK cells were whole-cell clamped at 23–25°C, 24–48 h after transfection, as described previously

(Bian *et al.* 2001; Suh *et al.* 2006). Data were analyzed using pClamp7 (Axon Instruments) and the Origin 6.0 program (OriginLab, Northampton, MA, USA). For all experiments with individual cells, at least three independent batches of cells were used in different experimental days.

Thin layer chromatograph

Anion-exchange high-performance liquid chromatography analysis of phosphoinositides and phosphoinositide radiolabeling using liposomes and [γ - 32 P]ATP were performed as described (Berman *et al.* 2008). Radioactivity was quantified using a phosphorimager. In some experiments, cytosols were pre-incubated for 5 min at 37°C with 1 mM GDP or 0.2 mM GTP- γ S. 'P2' subcellular fractions were prepared for metabolic labeling as follows: HEK cell was homogenized in 0.4 mL of 25 mM HEPES, pH 7.4, and 0.32 M sucrose (HEPES-based buffer), and centrifuged at 10 000 $\times g$ in a microfuge. The resulting supernatant was diluted in 4 mL HEPES-based buffer and centrifuged at 45 000 $\times g$ for 15 min at 4°C in an SS34 Sorvall centrifuge rotor. The pellet was re-suspended in 4 mL of 130 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 2 mM MgCl₂, 25 mM HEPES (pH 7.33) and 30 mM glucose (control buffer) and re-centrifuged and re-suspended in the same buffer at a final protein concentration of 2 mg/mL. Aliquots of 100 μ L were incubated with [32 P]orthophosphate at 2 mCi/mL for 30 min at 37°C. At the end of this incubation, samples were subjected to lipid extraction. Counts in the PIP₂ spot were normalized to those in the PA spot, which were not affected by the various genotypes. Lipids were extracted using chloroform/methanol (2 : 1) supplemented with 20 mg/mL cold phosphoinositides and processed for TLC.

ELISA for PIP₂

The amount of PIP₂ extracted from HEK293 cells were measured by using PIP₂ Mass ELISA kit (Echelon Biosciences Inc., Salt Lake City, UT, USA). PIP₂ was extracted from control or cholesterol-treated cell for 1 h at 150 μ M. Cellular PIP₂ quantities were estimated by comparing the values from standard curve, which showed linear relationship at the range from 0.5 to 1000 pM concentrations.

Results

Inhibition of endogenous MIC currents by cholesterol via depletion of PIP₂

The transient receptor potential melastatin 7 (TRPM7)-associated MIC channel has been implicated in the control of cellular proliferation and viability by transporting various trace metal ions, in the regulation of Mg²⁺ and Ca²⁺-homeostasis, and in anoxic neuronal death (Nadler *et al.* 2001; Aarts *et al.* 2003; Monteilh-Zoller *et al.* 2003; Schmitz *et al.* 2003). We measured endogenous MIC currents from HEK293 cells using the whole-cell patch clamp method in divalent cation-free bath solution. In agreement with a previous report (Jeong *et al.* 2006), MIC current recorded from control cells showed time-dependent activation, reaching a steady-state level approximately 400 s after obtaining whole-cell configuration (Fig. 1a). To determine if increasing the cholesterol level might regulate the activity of the MIC channel, we pre-incubated cells with 150 μ M cholesterol water-solubilized with M β CD-cholesterol for 1–2 h prior to recordings. Under these conditions, membranous cholesterol levels increased by more than twofold, while no cell death was observed (data not shown). MIC currents were down-regulated by over 90% with this treatment, as shown in Fig. 1(a). However, the normalized current traces from control and cholesterol-enriched cells showed similar time-dependent activation, indicating that the activation rate of MIC currents was not changed by cholesterol enrichment (inset of Fig. 1a). Current-voltage relationships were obtained by applying ramp voltage pulses (Fig. 1b). Control cells showed slightly inward rectification, which is typical of MIC current. Cholesterol enrichment did not alter the shape of this curve, but reduced the currents at all voltages. These results suggest that cholesterol enrichment

decreases the number of activated MIC channels. When cells were pre-incubated with M β CD alone for 1–2 h to deplete cholesterol, MIC currents were increased by twofold, which was opposite to the effect of M β CD-cholesterol (data not shown). M β CD did not change the time-dependent activation rate of MIC currents. These results verified that the effects of M β CD and M β CD-cholesterol on MIC currents were specific for cholesterol.

It has been shown that PIP₂, but not its metabolites such as diacylglycerol and IP₃, directly modulates TRPM7 channels (Runnels *et al.* 2002). Specifically, the finding that PIP₂ depletion inhibits TRPM7 channels led us to hypothesize that down-regulation of endogenous MIC currents by cholesterol enrichment may be due to decreased levels of PIP₂. To test this possibility, we determined if increasing PIP₂ levels could restore normal MIC currents in cholesterol-enriched cells. When water soluble DiC₈-PIP₂ (25 μ M) was directly applied to the cytoplasmic side of cells in the whole-cell configuration, MIC current was partially recovered as shown in Fig. 1(c). In contrast, application of the stereoisomer phosphatidylinositol 3,4-bisphosphate, PA, or phosphatidylinositol 3,4,5-trisphosphate was not as effective at rescuing MIC currents as PIP₂ at the same concentration (Fig. 1c). Next, the effect of cholesterol enrichment on other endogenous currents was tested in HEK293 cells. Neither CRAC current nor Kv current was inhibited by cholesterol enrichment (Fig. 1d). Thus, cholesterol enrichment inhibited MIC channels, but spared CRAC and Kv channels. Pre-incubating cells with M β CD alone for 1–2 h was without effect on CRAC current or Kv current (data not shown).

Inhibition of exogenously expressed HERG currents by cholesterol

To further test whether enhanced cholesterol levels down-regulate MIC currents by reducing PIP₂ levels, we investigated the effect of cholesterol-enrichment on other PIP₂-sensitive channels. K⁺ currents were measured in HEK293 cells over-expressing the HERG K⁺ channel, which has been implicated in the control of repolarization rate during the cardiac action potential (Bian *et al.* 2001). Exogenously expressed HERG K⁺ channels gave rise to very slow activation behavior (Fig. 2a), as reported previously (Bian *et al.* 2001). Similar to the recordings for MIC currents, testing for the effect of cholesterol enrichment on the HERG K⁺ current was carried out by pre-incubating cells with 150 μ M water-soluble cholesterol for 1–2 h before recordings. Cholesterol enrichment inhibited the HERG K⁺ current as shown in Fig. 2(a) for typical recordings. Increased cholesterol levels were inhibitory at all voltages tested, either when maximum currents were measured (Fig. 2b) or when tail currents were measured (Fig. 2c). The inclusion of 25 μ M PIP₂ in the whole-cell pipette solution partially recovered HERG K⁺ current from cholesterol-enriched cells (Fig. 2b and c). These results are consistent with a previous report showing that HERG K⁺ current is under the regulation of PIP₂ (Bian *et al.* 2004), and they strongly suggest that increased cholesterol induces depletion of PIP₂.

A pharmacological approach was used to determine if the acute manipulation of endogenous PIP₂ levels could regulate HERG K⁺ current. A major catabolic pathway for PIP₂ involves PLC-mediated hydrolysis of PIP₂ to generate diacylglycerol and IP₃ (Horowitz *et al.* 2005). We therefore used a PLC activator to down-regulate cellular PIP₂ levels. Figure 3(a) shows HERG K⁺ current traces measured by step voltage pulses before and after the application of 25 μ M *m*-3M3FBS, the active-form of PLC activator (Bae *et al.* 2003). The time-dependent change of current levels is shown in Fig. 3(b). Without drug treatment, control HERG K⁺ currents showed little run-down during the recordings. In contrast, application of the PLC activator induced very rapid inhibition of the current, while the inactive-form, *o*-3M3FBS, was without effect. Based on these results, we confirmed that acute depletion of PIP₂ inhibits HERG K⁺ current. We then tested the effect of acutely applied cholesterol on HERG K⁺ currents. As shown in Fig. 3(c), current inhibition started approximately 5 min after the application of water-soluble cholesterol. About 20% of current inhibition was achieved within 15 min. Thus, even though cholesterol enrichment was less effective and required more time than the PLC activator

did, both treatments induced similar acute inhibition of HERG K^+ current. These results suggest that the inhibitory effect of cholesterol enrichment on HERG K^+ currents may occur via the activation of PLC. To test this hypothesis, we included PLC inhibitors in the whole-cell pipette solution. As shown in Fig. 3(c), the presence of PLC inhibitor, 10 μ M edelfosine, in the pipette solution partially prevented the acute inhibitory effect of cholesterol. The acute effect of cholesterol was also prevented by the presence of structurally different PLC inhibitor, 5 μ M U73122 (Fig. 3d). Inclusion of PIP₂ in the whole-cell pipette solution also prevented cholesterol effect (Fig. 3d), which may suggest that the acute depletion of PIP₂ suffices to suppress PIP₂-sensitive HERG channels. However, the effect of PIP₂ on the acute cholesterol inhibition was different from that of PIP₂ on cholesterol effect from whole-cell patches in Fig. 2(b).

It is possible that PIP₂-induced increase in HERG current from cholesterol-treated cell is completely independent of the inhibitory effect of cholesterol. Thus, the recovery of HERG current by PIP₂ could occur by the overlap between cholesterol-induced inhibition and PIP₂-induced facilitation. To test this possibility, we pre-incubated cells with PLC inhibitor edelfosine (5 μ M) along with cholesterol for 1–2 h before recordings. As shown in Fig. 2(b) and (c), the addition of edelfosine prevented most of inhibitory effect of cholesterol on HERG current. Edelfosine alone was without effect on HERG current (data not shown). We also tested the effect of PLC inhibitors on the endogenous MIC currents. When 5 μ M edelfosine or 1 μ M U73122 were pre-incubated along with cholesterol, MIC current densities were 64.7 ± 6.0 pA/pF ($n = 9$) and 68.7 ± 7.5 pA/pF ($n = 8$), respectively. These values were similar to MIC current density from control cells (Fig. 1c). Therefore, the addition of PLC blockers prevented the inhibitory effect of cholesterol on MIC current as well. These results suggest that cholesterol enrichment inhibits either endogenous MIC current or exogenous HERG current via the membrane PIP₂ depletion by PLC activation.

Inhibition of KCNQ K^+ channels by cholesterol

Many cellular proteins, including ion channels and transporters, are inhibited when PIP₂ is hydrolyzed by PLC (Suh and Hille 2005). Although we showed that cholesterol enrichment depletes PIP₂, causing the down-regulation of PIP₂-sensitive MIC and HERG channels via the activation of PLC, we could not rule out other signaling molecules downstream of PLC or changes in other phospholipids. Recently, the depletion of PIP₂ has been shown to be sufficient to suppress KCNQ K^+ current without the need for other second messengers (Suh *et al.* 2006). Thus, we utilized HEK293-derived cell line tsA-201 cells expressing KCNQ channels to determine if cholesterol enrichment suppresses exogenously expressed KCNQ K^+ current. Families of current were elicited using voltage steps from -80 to $+40$ mV, in 10 mV intervals, in control and cholesterol-enriched cells (Fig. 4a). When voltage dependences of tail currents were compared, cholesterol-enriched cells showed a small rightward shift (data not shown). Deactivation and activation time constants were also increased by cholesterol enrichment. However, the most prominent effect of cholesterol enrichment on KCNQ K^+ channels was on current densities. When currents were measured immediately after whole-cell breakthrough, cholesterol-enriched cells showed only 27% of the current density level compared with control cells (Fig. 4b).

We tested the effects of PLC inhibitors on KCNQ K^+ currents. Pre-incubating cells with 2.5 μ M U73122 or 2.5 μ M edelfosine alone showed inhibitory effects on KCNQ K^+ currents as shown in Fig. 4(b). However, the presence of these blockers prevented the inhibitory effect of cholesterol on KCNQ K^+ currents (Fig. 4b). These results also suggest that cholesterol enrichment induces the depletion of PIP₂ via the activation of PLC. We also tested the acute effect of cholesterol on KCNQ K^+ currents. They showed slight rundown to 79% of the initial current at 20 min when measured at -20 mV (Fig. 4c). The acute application of cholesterol induced the inhibition of the current up to 53% of the initial current. In cells expressing M₁

muscarinic receptors, the application of muscarinic agonist oxotremorine-M following the application of cholesterol rapidly suppressed the current (Fig. 4d), confirming that depletion of PIP₂ inhibits KCNQ K⁺ currents.

Down-regulation of PIP₂ by cholesterol

We analyzed phosphoinositide turnover using a cell-free radiolabeling assay in the presence of [γ -³²P] (Di Paolo *et al.* 2004), and tested the effect of cholesterol enrichment on PIP₂ levels. We analyzed extracts prepared from control and cholesterol-enriched HEK293 cells using TLC (Fig. 5a) and found a 35% reduction in γ -³²P incorporation into PIP₂ in cholesterol-enriched cells, relative to control cells ($n = 4$; Fig. 5b). A considerable decrease in PA labeling was also observed in cholesterol-enriched cells, while there was no change in the labeling of phosphatidylinositol phosphates. Incorporation of radioactive phosphate into phospholipids could occur through lipid kinase-mediated phosphorylation, as well as through contributions from phosphatases and phospholipases. PIP₂ levels at steady state were also measured by using PIP₂ ELISA kit from HEK293 cells. Compared with control cells, cholesterol-enriched HEK293 cells showed $18.1 \pm 0.4\%$ ($n = 6$) reduction in PIP₂ level. Thus, our lipid analysis indicates that cholesterol enrichment depletes PIP₂ by either diminishing synthesis or enhancing breakdown of PIP₂.

Discussion

In this study, we show that cholesterol enrichment inhibits PIP₂-sensitive channels by down-regulating PIP₂ levels. We tested the effects of cholesterol on one of the endogenous non-selective channels (MIC) and two different exogenously expressed K⁺ channels (HERG and KCNQ). All of these channels are known to be positively regulated by PIP₂. As a growing number of channels are known to be under the regulation of PIP₂ (Suh *et al.* 2006), the activities of all these channels may be affected by plasma membrane cholesterol. However, the extent of modulation may not only be dependent on the expression of these ion channels in specific cells, but also on the sensitivity of a specific channel to PIP₂, because the regulation of ion channels by PIP₂ is dependent on the apparent affinity of the channel protein for PIP₂ (Gamper and Shapiro 2007).

Increasing PIP₂ levels restored MIC (Fig. 1c) and HERG currents (Fig. 2b and c) in cholesterol-enriched cells. In addition, addition of PLC inhibitors or PIP₂ to the pipette solution prevented the acute inhibitory effect of cholesterol on HERG K⁺ current (Fig. 3d). Also, we confirmed that the presence of PLC inhibitors prevented most of cholesterol effect on all of three channels tested. Thus, these results suggest that depletion of PIP₂ by cholesterol enrichment may occur through the activation of PLC. Activation of PLC by cholesterol was previously suggested to explain the mitogen-like action of cholesterol on ascites tumor cell growth and macromolecule synthesis (Haeffner and Wittmann 1999). Cholesterol enrichment may induce activation of PLC through several mechanisms. First, cholesterol may induce translocation of some PLC isoforms from the cytosol to the plasma membrane, where breakdown of PIP₂ may occur. Intracellular translocation of phosphoinositide-specific PLC- δ isoform to the cell surface is known to be cell cycle-dependent (Yagisawa *et al.* 2006). Second, cholesterol may activate PLC by promoting its phosphorylation (Kim *et al.* 2000). Third, cholesterol may increase the expression levels of PLC. We are currently investigating these possibilities.

Although PIP₂ is a minor component in the plasma membrane, it plays important regulatory roles in a variety of cell functions, such as rearrangement of the cytoskeleton and membrane trafficking (Di Paolo and De Camilli 2006). To explain the multiple roles of PIP₂, the concept of spatially confined PIP₂ pools was proposed (Janmey and Lindberg 2004). Cholesterol- and sphingolipid-rich rafts may serve to confine PIP₂ within the plasma membrane. Thus, the confinement of PIP₂ to rafts may allow PIP₂ hydrolysis to occur locally and restrict signaling

mechanisms to the site of activation (Pike and Miller 1998; Hur *et al.* 2004). However, this hypothesis, termed 'raft-delimited PIP₂ signaling,' has been disputed recently (van Rheenen *et al.* 2005). It is possible that the steady-state level of PIP₂ is determined by the concerted action of phosphoinositide kinases and phosphatases. Our results may suggest another way of regulating PIP₂ levels within specific micro-domains. Cholesterol content in a specific micro-domain may regulate PIP₂ levels via PLC activity. Interestingly, PLC β 1 is shown to localize in detergent-resistant membrane microdomain prepared from synaptic plasma membrane fraction of rat brain (Taguchi *et al.* 2007).

It has been suggested that cholesterol plays a crucial role in the development and maintenance of neuronal plasticity and function (Pfrieger 2003). Failure of cholesterol homeostasis has been suggested as the unifying cause of synaptic degeneration (Koudinov and Koudinova 2005). For example, there is evidence suggesting that cholesterol levels are closely connected to neurological disorders such as Alzheimer's disease (Puglielli *et al.* 2003). When cholesterol homeostasis is compromised in such neurodegenerative conditions, perturbation of PIP₂ levels may follow, according to our results. Consequently, the activities of PIP₂-sensitive ion channels change, leading to modifications not only in passive ionic permeability, but also in the active properties of the neurons, such as their action potentials. Interestingly, we found that the activation of MIC channels is chronically suppressed by the presence of familial Alzheimer's disease-associated mutant presenilin (Landman *et al.* 2006). The down-regulation of PIP₂ contributes to the observed channel deficits, as well as to the generation of amyloidogenic β -amyloid peptide, A β 42. Alternatively, a recent report has shown that the oligomeric form of A β decreases the level of PIP₂, resulting in synaptic dysfunction (Berman *et al.* 2008). These results suggest that PIP₂ may serve as the molecule linking cholesterol metabolism to the pathogenesis of Alzheimer's disease. Thus, membrane cholesterol content may share the same molecular mechanism with Alzheimer's disease-causing presenilin mutations (i.e. down-regulation of PIP₂).

Acknowledgments

This work was also supported by Samsung Biomedical Research Grant and Korea Research Foundation Grant funded by NIH grant R01 NS056049 (G.D.P.) and the Korean Government (KRF-2006-E00009) to S.C.

Abbreviations used

CRAC	calcium release-activated calcium
DMEM	Dulbecco's modified Eagle's medium
DMSO	dimethylsulfoxide
FBS	fetal bovine serum
HEK	human embryonic kidney
HERG	human <i>Ether-a-go-go</i> related gene
IP ₃	inositol trisphosphate
Kv current	voltage-dependent K ⁺ current
MIC	Mg ²⁺ -inhibitory cation channel
M β CD	methyl- β -cyclodextrin
PA	phosphatidic acid
PBS	phosphate-buffered saline
PIP ₂	phosphatidylinositol 4,5-bisphosphate

PLC phospholipase C
 TRPM7 transient receptor potential melastatin 7

References

- Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, MacDonald JF, Tymianski M. A key role for TRPM7 channels in anoxic neuronal death. *Cell* 2003;115:863–877. [PubMed: 14697204]
- Abi-Char J, Maguy A, Coulombe A, Balse E, Ratajczak P, Samuel JL, Nattel S, Hatem SN. Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes. *J. Physiol* 2007;582:1205–1217. [PubMed: 17525113]
- Bae YS, Lee TG, Park JC, Hur JH, Kim Y, Heo K, Kwak JY, Suh PG, Ryu SH. Identification of a compound that directly stimulates phospholipase C activity. *Mol. Pharmacol* 2003;63:1043–1050. [PubMed: 12695532]
- Berman DE, Dall'Armi C, Voronov SV, et al. Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. *Nat. Neurosci* 2008;11:547–554. [PubMed: 18391946]
- Bian J, Cui J, McDonald TV. HERG K⁺ channel activity is regulated by changes in phosphatidyl inositol 4,5-bisphosphate. *Circ. Res* 2001;89:1168–1176. [PubMed: 11739282]
- Bian JS, Kagan A, McDonald TV. Molecular analysis of PIP₂ regulation of HERG and IKr. *Am. J. Physiol. Heart Circ. Physiol* 2004;287:H2154–H2163. [PubMed: 15231497]
- Chang HM, Reitstetter R, Mason RP, Gruener R. Attenuation of channel kinetics and conductance by cholesterol: an interpretation using structural stress as a unifying concept. *J. Membr. Biol* 1995;143:51–63. [PubMed: 7714888]
- Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. *Nature* 2006;443:651–657. [PubMed: 17035995]
- Di Paolo G, Moskowitz HS, Gipson K, et al. Impaired PtdIns(4,5)P₂ synthesis in nerve terminals produces defects in synaptic vesicle trafficking. *Nature* 2004;431:415–422. [PubMed: 15386003]
- Fong TM, McNamee MG. Correlation between acetylcholine receptor function and structural properties of membranes. *Biochemistry* 1986;25:830–840. [PubMed: 3008814]
- Gamper N, Shapiro MS. Regulation of ion transport proteins by membrane phosphoinositides. *Nat. Rev. Neurosci* 2007;8:921–934. [PubMed: 17971783]
- Graziani A, Rosker C, Kohlwein SD, Zhu MX, Romanin C, Sattler W, Groschner K, Poteser M. Cellular cholesterol controls TRPC3 function: evidence from a novel dominant-negative knockdown strategy. *Biochemical J* 2006;396:147–155.
- Haeflner EW, Wittmann U. Cholesterol-induced growth stimulation, macromolecule synthesis, and increased phosphoinositide metabolism of ascites tumour cells in culture. *Cell. Signal* 1999;11:821–829. [PubMed: 10617285]
- Hajdu P, Varga Z, Pieri C, Panyi G, Gaspar R Jr. Cholesterol modifies the gating of Kv1.3 in human T lymphocytes. *Pflugers Arch* 2003;445:674–682. [PubMed: 12632187]
- Hermosura MC, Monteilh-Zoller MK, Scharenberg AM, Penner R, Fleig A. Dissociation of the store-operated calcium current *I*_{CRAC} and the Mg-nucleotide-regulated metal ion current MagNum. *J. Physiol* 2002;539:2.
- Horowitz LF, Hirdes W, Suh BC, Hilgemann DW, Mackie K, Hille B. Phospholipase C in living cells: activation, inhibition, Ca²⁺ requirement, and regulation of M current. *J. Gen. Physiol* 2005;126:243–262. [PubMed: 16129772]
- Hur EM, Park YS, Lee BD, Jang IH, Kim HS, Kim TD, Suh PG, Ryu SH, Kim KT. Sensitization of epidermal growth factor-induced signaling by bradykinin is mediated by c-Src. Implications for a role of lipid microdomains. *J. Biol. Chem* 2004;279:5852–5860. [PubMed: 14630916]
- Janmey PA, Lindberg U. Cytoskeletal regulation: rich in lipids. *Nat. Rev. Mol. Cell Biol* 2004;5:658–666. [PubMed: 15366709]

- Jeong SY, Shin SY, Kim HS, Bae CD, Uhm DY, Park MK, Chung S. Regulation of magnesium-inhibited cation current by actin cytoskeleton rearrangement. *Biochem. Biophys. Res. Commun* 2006;339(3): 810–815. [PubMed: 16325775]
- Kim MJ, Kim E, Ryu SH, Suh PG. The mechanism of phospholipase C- γ 1 regulation. *Exp. Mol. Med* 2000;32:101–109. [PubMed: 11048639]
- Koudinov AR, Koudinova NV. Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. *J. Neurol. Sci* 2005;229:233–240. [PubMed: 15760645]
- Lam RS, Shaw AR, Duszyk M. Membrane cholesterol content modulates activation of BK channels in colonic epithelia. *Biochim. Biophys. Acta* 2004;1667:241–248. [PubMed: 15581861]
- Landman N, Serban G, Shin SY, Kang MS, Chung S, Kim T-W. Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. *Proc. Natl. Acad. Sci. USA* 2006;103:19524–19529. [PubMed: 17158800]
- Levitan I, Christian AE, Tulenko TN, Rothblat GH. Membrane cholesterol content modulates activation of volume-regulated anion current in bovine endothelial cells. *J. Gen. Physiol* 2000;115:405–416. [PubMed: 10736308]
- Monteilh-Zoller MK, Hermosura MC, Nadler MJ, Scharenberg AM, Penner R, Fleig A. TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. *J. Gen. Physiol* 2003;121:49–60. [PubMed: 12508053]
- Nadler MJ, Hermosura MC, Inabe K, et al. LTRPC7 is a Mg-ATP-regulated divalent cation channel required for cell viability. *Nature* 2001;411:590–595. [PubMed: 11385574]
- Pfriege FW. Cholesterol homeostasis and function in neurons of the central nervous system. *Cell. Mol. Life Sci* 2003;60:1158–1171. [PubMed: 12861382]
- Pike LJ, Miller JM. Cholesterol depletion delocalizes phosphatidylinositol bisphosphate and inhibits hormone-stimulated phosphatidylinositol turnover. *J. Biol. Chem* 1998;273:22298–22304. [PubMed: 9712847]
- Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. *Nat. Neurosci* 2003;6:345–351. [PubMed: 12658281]
- van Rheenen J, Achame EM, Janssen H, Calafat J, Jalink K. PIP₂ signaling in lipid domains: a critical re-evaluation. *EMBO J* 2005;24:1664–1673. [PubMed: 15861130]
- Romanenko VG, Fang Y, Byfield F, Travis AJ, Vandenberg CA, Rothblat GH, Levitan I. Cholesterol sensitivity and lipid raft targeting of Kir2.1 channels. *Biophys. J* 2004;87:3850–3861. [PubMed: 15465867]
- Runnels LW, Yue L, Clapham DE. The TRPM7 channel is inactivated by PIP₂ hydrolysis. *Nat. Cell Biol* 2002;4:329–336. [PubMed: 11941371]
- Schmitz C, Perraud AL, Johnson CO, Inabe K, Smith MK, Penner R, Kurosaki T, Fleig A, Scharenberg AM. Regulation of vertebrate cellular Mg²⁺ homeostasis by TRPM7. *Cell* 2003;114:191–200. [PubMed: 12887921]
- Suh BC, Hille B. Regulation of ion channels by phosphatidylinositol 4,5-bisphosphate. *Curr. Opin. Neurobiol* 2005;15:370–378. [PubMed: 15922587]
- Suh BC, Inoue T, Meyer T, Hille B. Rapid chemically induced changes of PtdIns(4,5)P₂ gate KCNQ ion channels. *Science* 2006;314:1454–1457. [PubMed: 16990515]
- Taguchi K, Kumanogoh H, Nakamura S, Maekawa S. Localization of phospholipase C β 1 on the detergent-resistant membrane microdomain prepared from synaptic plasma membrane fraction of rat brain. *J. Neurosci. Res* 2007;85:1364–1371. [PubMed: 17348042]
- Tsujikawa H, Song Y, Watanabe M, Masumiya H, Gupte SA, Ochi R, Okada T. Cholesterol depletion modulates basal L-type Ca²⁺ current and abolishes its β -adrenergic enhancement in ventricular myocytes. *Am. J. Physiol. Heart Circ. Physiol* 2008;294:H285–H292. [PubMed: 17982015]
- Yagisawa H, Okada M, Naito Y, Sasaki K, Yamaga M, Fujii M. Coordinated intracellular translocation of phosphoinositidespecific phospholipase C-delta with the cell cycle. *Biochim. Biophys. Acta* 2006;1761:522–534. [PubMed: 16580873]

Fig. 1.

Inhibition of endogenous Mg^{2+} -inhibitory cation channel (MIC) currents by cholesterol enrichment. (a) Time-dependent activation profile of MIC currents. Currents at -100 mV were plotted in control ($n = 6$; $\circ$) and cholesterol-treated HEK293 cells ($n = 6$; $\bullet$). Cells were pre-incubated for 1–2 h with $150 \mu M$ cholesterol before recordings. MIC currents were elicited by ramp pulses from -100 to $+100$ mV every 10 s using whole-cell configurations bathed in Ca^{2+} -free bath solution. The inset shows the normalized MIC currents from control and cholesterol-treated cells. Currents were normalized relative to the maximum current levels in each condition. (b) Current–voltage relationships of the MIC current. Currents were obtained in response to ramp pulses from -100 to $+100$ mV during a 200-ms period in control and cholesterol-treated cells. Currents were elicited 500 s after the formation of whole cell-configuration to induce full activation of MIC currents. A dotted line is drawn over the control current trace to show the inward rectification of the MIC current. (c) Recovery of MIC currents by phosphatidylinositol 4,5-bisphosphate (PIP₂) in cholesterol-treated HEK293 cells. In some recordings, $25 \mu M$ PIP₂, phosphatidylinositol 3,4-bisphosphate [PI(3,4)P₂], phosphatidic acid (PA), or phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P₃] was included in the pipette solution. (d) Effects of cholesterol enrichment on other endogenous currents from HEK293 cells. Ca^{2+} release-activated Ca^{2+} (CRAC) currents and voltage-dependent K^{+} (Kv) currents were measured in control and cholesterol-treated HEK293 cells, and current density values (pA/pF) are presented.

Fig. 2.

Inhibition of exogenously expressed ether-a-go-go-related gene (HERG) currents by cholesterol enrichment. (a) Representative HERG K⁺ current traces are shown in control and cholesterol-treated HEK293 cells. Cells were pre-incubated for 1–2 h with 150 μ M cholesterol before recordings. Depolarizing steps were applied from a holding potential of -70 mV to between -60 and $+50$ mV for 4 s, followed by a step to -40 mV to elicit currents. As more depolarized membrane potentials were applied, HERG K⁺ currents were activated more rapidly, as evident in control current traces. (b, c) Averaged current–voltage relations obtained for HERG K⁺ currents ($n = 7$). Currents were measured at the end of the depolarizing step ($I_{\text{HERG,step}}$) and for peak tail current amplitude ($I_{\text{HERG,tail}}$) following the step to -40 mV. This pulse protocol was applied at 15 s intervals. In some recordings in cholesterol-treated cells, 25 μ M phosphatidylinositol 4,5-bisphosphate (PIP₂) was included in the pipette solution (+PIP₂). In some recordings, cells were treated with cholesterol along with phospholipase C inhibitor, 5 μ M edelfosine (+Edel).

Fig. 3.

Inhibition of ether-a-go-go-related gene (HERG) currents by acute application of phospholipase C (PLC) activator and cholesterol. (a) The effect of acute application of a PLC activator on the HERG current. Representative current traces show HERG K^+ current before (0 min) and after (1, 2, 3 and 5 min) the application of the PLC activator, *m*-3M3FBS (25 μ M). Currents were elicited by depolarizing voltage step to +30 mV from a holding potential of -70 mV for 4 s, followed by a step to -40 mV. (b) Steady state currents ($I_{HERG,step}$) were measured in different conditions. PLC activator (*m*-3M3FBS; $n = 6$) or non-active form (*o*-3M3FBS; $n = 8$) was added at the time indicated by the arrow. Vehicle (DMSO) was added for control ($n = 6$). (c) Steady state currents ($I_{HERG,step}$) were measured in different conditions. The effect of 150 μ M cholesterol is shown (cholesterol; $n = 8$). In some cells, the PLC inhibitor edelfosine (10 μ M) (cholesterol + Edel; $n = 8$), were included in whole-cell pipette solutions. Vehicle DMSO was added for control (control; $n = 8$). Cholesterol was added at the time indicated by the arrow. (d) Comparison of average steady state HERG K^+ currents expressed as % of control. The data were the same as in (c) except for the PLC inhibitors U73122 ($n = 4$). The presence of 25 μ M PIP₂ in the pipette solution also blocked the inhibitory effect of cholesterol ($n = 7$).

Fig. 4.

Inhibition of KCNQ current by cholesterol enrichment. (a) Inhibition of exogenously expressed KCNQ2/KCNQ3 K^+ current by cholesterol. Families of K^+ current elicited by voltage steps from -80 to +40 mV, in 10-mV intervals (see the pulse protocol), with or without incubation of 150 μ M cholesterol for 1–2 h (Control vs. Cholesterol in the figure). The holding potential was -70 mV. (b) Current density measured immediately after whole-cell breakthrough in control and cholesterol-treated cells. Cells expressing KCNQ channels were preincubated at 37°C for 2 h in the presence or absence of cholesterol (150 μ M). Control, 95.7 ± 14.6 pA/pF; cholesterol, 23.0 ± 6.4 pA/pF, $n = 7$. $*p < 0.01$. In some cells, U73122 (2.5 μ M) or edelfosine (2.5 μ M) was pre-incubated with or without cholesterol for 2 h at 37°C. (c) Time course of KCNQ current modulation by acute application of cholesterol (150 μ M). Measurements started 3 min after breaking through to whole-cell recording at 23–25°C. Vertical bars are SEM. Control, $n = 3$; cholesterol, $n = 5$. (d) Modulation of KCNQ current by cholesterol and oxotremorine-M (Oxo-M). Whole-cell currents were recorded during the application of cholesterol (150 μ M) and Oxo-M (10 μ M).

Fig. 5. Down-regulation of phosphatidylinositol 4,5-bisphosphate (PIP₂) by cholesterol. (a) Alteration of PIP₂ metabolism in cholesterol-treated cells. TLC analysis of lipid extracts prepared either from control or cholesterol-treated (150 μ M for 2 h) HEK293 cells. PIP, phosphatidylinositol 4-monophosphate. (b) Quantification of TLC data.